Katrina Rolen, MD
Medical Oncology · Lewiston, IDNPI 1821042029
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.2% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Amgen at 26.6% of the total. Reporting peaked in 2019 at $824 and has fallen 97.9% since, to $17 in 2022.
Across 55 payments — averaging $17.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$252
- E.r. Squibb & Sons, L.L.C.$202
- Taiho Oncology, Inc.$85
- Johnson & Johnson$74
- Novartis$59
- Merck$53
- plus $222 from 9 others
What the payments were for
- Food & beverage$89294%
- Education$556%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 14 | $252 |
| E.r. Squibb & Sons, L.L.C. | 15 | $202 |
| Taiho Oncology, Inc. | 2 | $85 |
| Johnson & Johnson(2 entities) | 5 | $74 |
| Novartis | 3 | $59 |
| Merck | 3 | $53 |
| Array Biopharma Inc | 3 | $45 |
| Genentech USA, Inc. | 3 | $44 |
| Terumo Medical Corporation | 1 | $42 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Pfizer | 1 | $18 |
| Bristol Myers Squibb | 1 | $16 |
| Bayer | 1 | $15 |
| Gilead | 1 | $12 |
| Seagen Inc. | 1 | $12 |
How this compares
Too few medical oncology providers in Idahoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 119 | $2,215 |
| Hydroxyurea | 16 | $647 |
| Anastrozole | 30 | $570 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Lewiston
- Sushma PantLewiston$8K
- Gerardo MidenceLewiston$1K
- Daniel WilliamsLewiston$1K
- Abeer ArainLewiston$649
- Muhammad BegBoise$99K
- Travis WilliamsMeridian$50K
- Cannon MilaniBoise$9K
- Gwendoline FonebiPocatello$675
- Cameron ShumwayCoeur D Alene$404
- Jonathan SwerdloffNampa$369
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.